ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Pre-Mkt 03-20 05:00:01 EDT

15.02

+0.15

+1.01%

High15.15	Low14.53	Vol5.62M
Open14.75	D1 Closing14.87	Amplitude4.17%
Mkt Cap3.57B	Tradable Cap3.51B	Total Shares238.00M
T/O83.22M	T/O Rate2.40%	Tradable Shares233.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":15.02,"timestamp":1773950400000,"preClose":14.87,"halted":0,"volume":5615903,"delay":0,"changeRate":0.010087424344317442,"floatShares":233862209,"shares":237997765,"eps":0.6,"marketStatus":"Pre-Mkt","change":0.15,"latestTime":"03-20 05:00:01 EDT","open":14.75,"high":15.15,"low":14.53,"amount":83222235.03409,"amplitude":0.041695,"askPrice":15.19,"askSize":199,"bidPrice":14.93,"bidSize":199,"shortable":3,"etf":0,"ttmEps":0.6,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774013400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":15.02,"postHourTrading":{"tag":"盘后","latestPrice":15,"preClose":15.02,"latestTime":"18:39 EDT","volume":128046,"amount":1922537.03,"timestamp":1773959961015,"change":-0.02,"changeRate":-0.001332,"amplitude":0.001332},"volumeRatio":1.7928769327532572,"impliedVol":0.5986,"impliedVolPercentile":0.56},"requestUrl":"/m/hq/s/ADMA/wiki","defaultTab":"wiki","newsList":[{"id":"2620078794","title":"ADMA Biologics President and CEO Adam S. Grossman disposes of USD 318,360 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620078794","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620078794?lang=en_us&edition=fundamental","pubTime":"2026-03-18 09:01","pubTimestamp":1773795662,"startTime":"0","endTime":"0","summary":"Adam Grossman, President and CEO of ADMA Biologics, reported a disposal of 21,000 common shares on March 16, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4fpZRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ADMA Biologics President and CEO Adam S. Grossman disposes of USD 318,360 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2620763704","title":"FDA-Approved Yield Boost For ASCENIV Might Change The Case For Investing In ADMA Biologics (ADMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620763704","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620763704?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:21","pubTimestamp":1773753665,"startTime":"0","endTime":"0","summary":"ADMA Biologics recently reported strong 2025 performance driven by higher demand for its immune globulin therapy ASCENIV, alongside improved payer coverage and confidence in long-term plasma supply that together provide clearer visibility into 2026 revenue acceleration.\nThe FDA’s approval of a yield-enhancement manufacturing process is particularly important, as it is expected to lift production efficiency while supporting higher margins and longer-term capital return efforts.\nNow we’ll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/fda-approved-yield-boost-for-asceniv-might-change-the-case-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/fda-approved-yield-boost-for-asceniv-might-change-the-case-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","US7Y.BOND","TMF","US10Y.BOND","BK4588","BK4585","US2Y.BOND","US30Y.BOND","US5Y.BOND","LABU","US6M.BOND","US12M.BOND","US3Y.BOND","ADMA","TLTW"],"gpt_icon":1},{"id":"2618604341","title":"Insider Confidence Surges as ADMA Biologics Director Makes Bold Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604341","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618604341?lang=en_us&edition=fundamental","pubTime":"2026-03-10 10:01","pubTimestamp":1773108113,"startTime":"0","endTime":"0","summary":"New insider activity at ADMA Biologics ( ($ADMA) ) has taken place on March 9, 2026. Director Steve Elms has made a notable insider purchase of ADM...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-confidence-surges-as-adma-biologics-director-makes-bold-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-confidence-surges-as-adma-biologics-director-makes-bold-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2617456387","title":"Is ADMA Biologics (ADMA) Attractive After Recent Share Price Swings And DCF Upside?","url":"https://stock-news.laohu8.com/highlight/detail?id=2617456387","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617456387?lang=en_us&edition=fundamental","pubTime":"2026-03-05 02:34","pubTimestamp":1772649292,"startTime":"0","endTime":"0","summary":"If you are wondering whether ADMA Biologics at around US$16.38 is offering fair value or an opportunity, you are in the right place to unpack what the current price actually reflects.\nThe stock has had a mixed run, with a 5.5% gain over the last 7 days, a 5.3% decline over the past 30 days, and an 8.4% decline year to date, following a very large 3-year return and around 7x over 5 years.\nRecent coverage has focused on ADMA Biologics as a listed plasma based biopharmaceutical company, with...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/is-adma-biologics-adma-attractive-after-recent-share-price-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/is-adma-biologics-adma-attractive-after-recent-share-price-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4139","ADMA"],"gpt_icon":0},{"id":"1125901366","title":"Stock Track | ADMA Biologics Soars 5.20% Intraday on $125 Million Share Repurchase Announcement with JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=1125901366","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125901366?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:43","pubTimestamp":1772462580,"startTime":"0","endTime":"0","summary":"ADMA Biologics' stock surged 5.20% during intraday trading on Monday, following the company's announcement of a significant capital return initiative.The biopharmaceutical company revealed a planned...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2616339035","title":"ADMA Biologics launches $125 million accelerated share repurchase with JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339035","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339035?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452857,"startTime":"0","endTime":"0","summary":"ADMA Biologics announced a planned 2026 share repurchase initiative of about $200 million, including a $125 million accelerated share repurchase agreement with JPMorgan under its existing program authorizing up to $500 million in repurchases.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL14FcNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2430703095.HKD","LU1720051017.SGD","LU0882574139.USD","SG9999002232.USD","LU2023250330.USD","LU2552382058.USD","LU2592432038.USD","LU0868494708.USD","BK4112","ADMA","LU2237443465.HKD","LU0310799852.SGD","LU1244550221.USD","LU0820561818.USD","LU1720051108.HKD","LU0971096721.USD","IE00BJTD4V19.USD","LU0942090050.USD","LU0211328371.USD","LU0256863811.USD","LU0689472784.USD","LU2456880835.USD","LU2242649171.HKD","LU0683600562.USD","BK4207","LU2746668461.USD","LU0106831901.USD","LU1670627923.USD","LU0964807845.USD","LU1244550577.SGD","LU2505996509.AUD","IE00BKDWB100.SGD","IE00BDCRKT87.USD","LU0820562030.AUD","NDAQ","LU1551013425.SGD","IE00B64PRP62.GBP","LU2417539215.USD","LU1366192091.USD","JPM","LU2210149790.SGD","LU0211331839.USD","LU0048584097.USD","BK4504","IE00BBT3K403.USD","LU2381873111.SGD","LU0976567544.SGD","LU2210150020.SGD","IE0034235188.USD","JPMO"],"gpt_icon":1},{"id":"2614001894","title":"ADMA Biologics Files Initial Beneficial Ownership Statement for CFO and Treasurer Terry Kohler","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001894","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614001894?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:00","pubTimestamp":1772157646,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc. filed an initial statement of beneficial ownership for Terry Kohler, CFO and Treasurer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL7X26Qk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2614050602","title":"BRIEF-ADMA Biologics Says Brad Tade Is Retiring As Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050602","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050602?lang=en_us&edition=fundamental","pubTime":"2026-02-26 07:04","pubTimestamp":1772060667,"startTime":"0","endTime":"0","summary":"BRIEF-ADMA Biologics Says Brad Tade Is Retiring As Chief Financial OfficerFeb 25  - ADMA Biologics Inc ADMA.O:ADMA BIOLOGICS INC - ON FEB 20, BRAD TADE NOTIFIED CO HE IS RETIRING AS CHIEF FINANCIAL OFFICER - SEC FILINGADMA BIOLOGICS INC - TERRY KOHLER TO SUCCEED BRAD TADE AS CFO - SEC FILINGADMA BIOLOGICS INC: TADE WILL SERVE AS A CONSULTANT TO THE COMPANYFurther company coverage: ADMA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL23S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2614379052","title":"ADMA Biologics Inc: Tade Will Serve as a Consultant to the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2614379052","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614379052?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:09","pubTimestamp":1772057355,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL23S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2614052378","title":"ADMA Biologics Inc - Terry Kohler to Succeed Brad Tade as CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2614052378","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614052378?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:09","pubTimestamp":1772057355,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL23S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2614052333","title":"Earnings Flash (ADMA) ADMA Biologics Posts Q4 EPS $0.20, vs. FactSet Est of $0.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2614052333","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614052333?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:03","pubTimestamp":1772057030,"startTime":"0","endTime":"0","summary":"Earnings Flash (ADMA) ADMA Biologics Posts Q4 EPS $0.20, vs. FactSet Est of $0.19","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADMA"],"gpt_icon":0},{"id":"2614052897","title":"GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Revenue to Exceed $635M, vs. FactSet Est of $633.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2614052897","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614052897?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:00","pubTimestamp":1772056823,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Revenue to Exceed $635M, vs. FactSet Est of $633.8M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADMA"],"gpt_icon":0},{"id":"2614056062","title":"ADMA Biologics Q4 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $139.163M Miss $139.400M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614056062","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614056062?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:15","pubTimestamp":1772054109,"startTime":"0","endTime":"0","summary":"ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.18 by 16.22 percent. This is a 53.57 percent increase over earnings of $0.14 per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50867768/adma-biologics-q4-adj-eps-0-21-beats-0-18-estimate-sales-139-163m-miss-139-400m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ADMA Biologics Q4 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $139.163M Miss $139.400M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"gpt_icon":0},{"id":"2614892056","title":"CORRECTED-BRIEF-ADMA Biologics Q4 Revenue USD 139.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614892056","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614892056?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:05","pubTimestamp":1772053553,"startTime":"0","endTime":"0","summary":"CORRECTED-BRIEF-ADMA Biologics Q4 Revenue USD 139.2 Million\n\n\nFeb 25 (Reuters) - ADMA Biologics Q4 adjusted net income USD 52.6 million.\n\nQ4 net income USD 49.4 million\nQ4 adjusted EBITDA USD 73.6 million\noutlook FY revenue USD 635 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLX963DBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2614557220","title":"ADMA Biologics Outlook FY Revenue USD 635 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614557220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614557220?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:05","pubTimestamp":1772053508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLX963DBD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2614305209","title":"Corrected-ADMA Biologics Q4 Net Income USD 49.4 Million (Corrects Amount)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614305209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614305209?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:05","pubTimestamp":1772053508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLX963DBD:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2612446612","title":"ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446612","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446612?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:00","pubTimestamp":1771416000,"startTime":"0","endTime":"0","summary":"Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Feb.  18, 2026  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240055/33130/en/ADMA-Biologics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-25-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4141","ADMA","BK4139","PI"],"gpt_icon":0},{"id":"2612973624","title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612973624","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612973624?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:40","pubTimestamp":1771382418,"startTime":"0","endTime":"0","summary":"Adam S. Grossman, President and CEO of ADMA Biologics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL6ZlynS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2602510485","title":"GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Total Revenue About $635M, vs. FactSet Est of $631.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510485","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510485?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:12","pubTimestamp":1768223552,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Total Revenue About $635M, vs. FactSet Est of $631.9M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADMA","TSS"],"gpt_icon":0},{"id":"2602170055","title":"ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602170055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602170055?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222843,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc. reported preliminary unaudited full year  2025 total revenue of approximately USD 510-511 million. Year-end 2025 cash holdings grew to around USD 88 million, with an estimated operating cash flow of about USD 40 million generated in the fourth quarter  of 2025. The company reiterated its guidance for FY 2025 adjusted EBITDA and adjusted net income. ADMA Biologics Inc. expects FY 2026 and FY 2027 revenue to reach approximately USD 635 million and USD 775 million, respectively. Adjusted net income is projected at around USD 255 million in FY 2026 and USD 315 million in FY 2027. Adjusted EBITDA is forecasted to be about USD 360 million in FY 2026 and USD 455 million in FY 2027. The company maintains its long-term target of generating over USD 1.1 billion in annual revenue and more than USD 700 million in adjusted EBITDA by FY 2029.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLcfXHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","BK4112","SG9999014005.SGD","ADMA","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4585","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4588","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":-0.0583},{"period":"3month","weight":-0.2329},{"period":"6month","weight":-0.0559},{"period":"1year","weight":-0.2712},{"period":"ytd","weight":-0.1765}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.021016},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01871},{"month":3,"riseRate":0.583333,"avgChangeRate":0.096179},{"month":4,"riseRate":0.636364,"avgChangeRate":0.024806},{"month":5,"riseRate":0.636364,"avgChangeRate":0.053968},{"month":6,"riseRate":0.181818,"avgChangeRate":-0.056361},{"month":7,"riseRate":0.727273,"avgChangeRate":0.105206},{"month":8,"riseRate":0.272727,"avgChangeRate":0.003287},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.032166},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.041559},{"month":11,"riseRate":0.636364,"avgChangeRate":0.093715},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.060542}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction